On 2026-08-24, the U.S. FDA approved the Elecsys pTau217 biomarker blood test developed by Roche and Eli Lilly to identify Alzheimer's-related brain changes in patients aged 55 and older, following European approval in May 2026.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance Reuters
this outlet adds: share, google, ksdi9nmuwxup, food, drug, administration, cleared, partner
The nod follows European approval for the Elecsys pTau217 test in May.
FDA clears Roche and Eli Lilly blood test to identify Alzheimer's signs in patients aged 55 and older The Elecsys pTau217 biomarker test helps identify Alzheimer's-related brain changes in patients aged 55 and older with cognitive decline. https:// newsnews.ai/article/fda-clears -roche-eli-lilly-alzheimers-blood-test # UnitedStates # Roche # EliLilly